Nonallergic rhinitis is a syndrome of neurogenic hyperreactivity

Nonallergic rhinitis affects an estimated 20% to 70% of adults, often beginning after age 20, and is increasingly understood as a syndrome of neurogenic hyperreactivity rather than a simple inflammatory disorder.

Key Clinical Takeaways:
• Nonallergic rhinitis prevalence ranges widely from 20% to 70% in adults, with a European analysis reporting a crude prevalence of 10.9%.
• Experts classify the disorder into inflammatory endotypes (type 2 and non-type 2) and a reflex neurogenic endotype driven by autonomic imbalance and sensory receptor activation.
• Treatment options must target underlying physiological pathways, utilizing agents like nasal corticosteroids, antihistamines, anticholinergics, or sympathomimetics depending on the specific symptom profile.

Pathophysiologic Endotypes of Chronic Rhinitis

Chronic rhinitis involves persistent and heterogeneous inflammatory conditions of the nasal mucosa, classified by pathophysiologic mechanisms rather than clinical presentation alone. Speaking at the Rhinoforum conference held from June 18 to 20, 2026, in Bordeaux, France, Semia Sahtout Jouini, an ENT specialist in Tunis, Tunisia, explained that allergic rhinitis is IgE-mediated and can be seasonal or perennial. In contrast, nonallergic, noninfectious rhinitis refers to inflammatory conditions not mediated by immunoglobulin E.

Sahtout Jouini noted that chronic rhinitis divides into three major groups where allergic and nonallergic components frequently coexist: IgE-mediated allergic rhinitis, nonallergic noninfectious rhinitis, and mixed rhinitis. Nonallergic noninfectious rhinitis encompasses idiopathic rhinitis or nonallergic rhinopathy, chronic nonallergic eosinophilic rhinitis, senile, hormonal, tobacco-related, gustatory, drug-induced, and occupational forms.

Practically speaking, nonallergic rhinitis classifies into two main progressive pathophysiologic pathways. The first involves inflammation that is either type 2 or non-type 2. The type 2 eosinophilic profile features a response dominated by interleukin-4, interleukin-5, and interleukin-13 associated with chronic nonallergic eosinophilic rhinitis, which typically responds well to intranasal corticosteroids. The non-type 2 profile is dominated by neutrophils, associated with nasal dysbiosis, biofilm formation, and T1/T3 pathway activation, making it frequently corticosteroid-resistant.

Neurogenic Pathways Drive Nonallergic Rhinitis Mechanisms

Alongside inflammatory pathways, a neurogenic pathway drives nonallergic rhinitis through two distinct mechanisms. The first stems from an autonomic nervous system imbalance featuring decreased sympathetic tone and increased parasympathetic activity, leading to intermittent mucosal swelling, congestion, and watery rhinorrhea triggered by physical stimuli, temperature changes, and humidity. The second corresponds to neuroinflammation present in occupational, gustatory, and idiopathic forms.

Temperature changes, odors, and environmental irritants activate transient receptor potential ion channels in the nasal mucosa, triggering symptoms through a reflex arc combining sensory afferent and neurovegetative efferent components. This nervous hyperreactivity establishes the nerve as a therapeutic target alongside conventional anti-inflammatory approaches, according to the presentation at Rhinoforum 2026.

Targeted Treatment Strategies and Limitations

As detailed in clinical management guidelines, managing nonallergic rhinitis requires directing treatment toward underlying causative physiology rather than applying therapies randomly. Nasal corticosteroids serve as a first-line therapy, reducing inflammation, promoting smooth-muscle relaxation, and decreasing airway hyperresponsiveness, while remaining particularly useful for eosinophilic syndromes like chronic nonallergic eosinophilic rhinitis.

Nasal antihistamines competitively block type 1 histamine receptors. However, as noted in clinical management guidelines, they offer limited benefit unless symptoms stem directly from histamine release, though azelastine spray holds a labeled indication for vasomotor rhinitis due to combined antihistamine and anti-inflammatory actions. For patients presenting exclusively with rhinorrhea, ipratropium bromide acts as a topical anticholinergic with minimal systemic absorption, though it lacks efficacy against sneezing, itching, or nasal congestion.

Sympathomimetics utilize alpha-2 adrenergic agonistic properties or combined adrenergic stimulation to induce local vasoconstriction, reducing blood flow to the nasal mucosa by 30% to 40% for short-term obstruction relief. However, topical formulations carry risks of rhinitis medicamentosa if used beyond five to ten days.

Urbanization and Comorbidity Risks

The prevalence of nonallergic rhinitis is rising alongside urbanization and greater environmental irritant exposure, though precise estimation remains challenging due to the lack of a uniform definition or international consensus. European data including 20,772 participants calculated crude prevalences of 28% for allergic rhinitis and 10.9% for nonallergic rhinitis.

Patients with rhinitis, including nonallergic forms, face an elevated risk for several comorbidities. These associated health conditions include chronic rhinosinusitis, chronic cough, sleep apnea syndrome, and asthma.

Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.